Protocol Ledger

NCT06679140 · Phase III · RECRUITING

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Interventional Phase III clinical trial protocol NCT06679140 sponsored by Pfizer in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-08 Enrollment: 2,330 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06679140
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2,330 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06679140
Protocol FieldVerified Registry Value
NCT IdentifierNCT06679140
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment2,330 participants (ESTIMATED)
Registered Start Date2024-12-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06679140
Hospital Research SiteLocationSite Profile
Velocity Clinical Research (Huntington Park)Huntington Park, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI